What Is Retatrutide?

Research Overview

Retatrutide (LY3437943) is a first-in-class incretin-based triple hormone receptor agonist developed by Eli Lilly and Company that simultaneously engages three distinct metabolic receptor pathways. The molecule was first described by Coskun et al. in a 2022 publication in Cell Metabolism, detailing its discovery, mechanism, and early pharmacological characterization in preclinical models.[4]

Structurally, retatrutide is a 39-amino acid synthetic peptide engineered from a GIP peptide backbone. It incorporates three non-coded amino acid residues — two α-aminoisobutyric acid (Aib) residues at positions 2 and 20, and one α-methyl-L-leucine residue at position 13 — to enhance metabolic stability and receptor binding. A C20 fatty diacid moiety is conjugated at lysine-17 via an AEEA-γGlu linker, promoting albumin binding and extending the plasma half-life to approximately 6 days.[4][8]

The foundational pharmacological rationale for retatrutide rests on the hypothesis that simultaneously activating receptors for GLP-1, GIP, and glucagon can produce a distinct metabolic signaling profile compared to mono- or dual-receptor agonists. GLP-1 receptor agonism is associated with insulin-secretion signaling; GIP receptor agonism enhances the insulinotropic response and supports lipid metabolism; and critically, glucagon receptor agonism increases energy expenditure and drives lipolysis and hepatic fatty acid oxidation — a mechanism absent from existing dual agonists like tirzepatide.[1][10][11]

This research profile is limited to receptor pharmacology, in vitro data and preclinical (animal) literature. Human clinical-trial outcomes, doses and administration schedules are outside the scope of this research-use-only page; researchers should consult the cited primary literature directly.

Published preclinical work has examined retatrutide in rodent models of hepatic lipid metabolism, renal function and tumor biology. Marathe et al. (2025) reported reduced tumor engraftment and delayed tumor onset in mouse models compared with semaglutide,[14] and Ma et al. (2025) reported reduced inflammatory and fibrotic processes in the kidneys of diabetic db/db mice.[15]

For laboratory research use only. Not for human or veterinary use.